A detailed history of Two Sigma Investments, LP transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 282,547 shares of LYRA stock, worth $50,858. This represents 0.0% of its overall portfolio holdings.

Number of Shares
282,547
Previous 490,861 42.44%
Holding current value
$50,858
Previous $137,000 46.72%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.24 - $0.34 $49,995 - $70,826
-208,314 Reduced 42.44%
282,547 $73,000
Q2 2024

Aug 14, 2024

BUY
$0.26 - $6.25 $79,850 - $1.92 Million
307,118 Added 167.15%
490,861 $137,000
Q1 2024

May 15, 2024

BUY
$4.55 - $6.53 $232,673 - $333,924
51,137 Added 38.56%
183,743 $1.14 Million
Q4 2023

Feb 14, 2024

BUY
$2.82 - $5.24 $327,644 - $608,814
116,186 Added 707.59%
132,606 $694,000
Q3 2023

Nov 14, 2023

BUY
$2.95 - $4.8 $48,439 - $78,816
16,420 New
16,420 $64,000
Q2 2022

Aug 15, 2022

BUY
$4.12 - $7.51 $55,566 - $101,287
13,487 New
13,487 $76,000
Q1 2022

May 16, 2022

SELL
$3.5 - $5.36 $62,058 - $95,038
-17,731 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$4.22 - $9.41 $18,344 - $40,905
4,347 Added 32.48%
17,731 $77,000
Q3 2021

Nov 15, 2021

SELL
$6.06 - $9.43 $63,629 - $99,015
-10,500 Reduced 43.96%
13,384 $122,000
Q2 2021

Aug 16, 2021

SELL
$6.91 - $12.59 $332,840 - $606,435
-48,168 Reduced 66.85%
23,884 $192,000
Q1 2021

May 17, 2021

BUY
$10.38 - $15.61 $514,245 - $773,350
49,542 Added 220.09%
72,052 $835,000
Q4 2020

Feb 16, 2021

BUY
$9.28 - $13.88 $208,892 - $312,438
22,510 New
22,510 $257,000
Q3 2020

Nov 16, 2020

SELL
$10.61 - $13.96 $218,788 - $287,869
-20,621 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$10.91 - $18.56 $224,975 - $382,725
20,621 New
20,621 $234,000

Others Institutions Holding LYRA

About Lyra Therapeutics, Inc.


  • Ticker LYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,826,400
  • Market Cap $5.73M
  • Description
  • Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...
More about LYRA
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.